Peak Bio, Inc.

Peak Bio, Inc., formerly known as Ignyte Acquisition Corp and trading under the ticker IGNY, is a biopharmaceutical company that completed its de-SPAC merger after Ignyte Acquisition Corp went public in 2021 with a focus on the healthcare and life sciences sector. Sponsored by Ignyte Sponsor LLC, the blank-check company targeted innovative biotech opportunities before combining with Peak Bio, a developer of next-generation antibody-drug conjugates for oncology. The company filed an 8-K current report on November 7, 2024, under accession number 0000950170-24-123517, disclosing a material corporate event. Sign up on SpacDesk for full filing details, sponsor history, and real-time deal tracking on IGNY and hundreds of other SPAC transactions.